{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:23:30Z","timestamp":1790490210454,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"24","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.vaccine.2015.04.025","type":"journal-article","created":{"date-parts":[[2015,4,25]],"date-time":"2015-04-25T17:18:26Z","timestamp":1429982306000},"page":"2793-2799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults"],"prefix":"10.1016","volume":"33","author":[{"given":"Richard","family":"McFetridge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoke Sobanjo-ter","family":"Meulen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Folkerth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Hoekstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Dallas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia A.","family":"Hoover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocio D.","family":"Marchese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Zacholski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy J.","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon E.","family":"Stek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Hartzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luwy K.","family":"Musey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.04.025_bib0240","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.285.13.1729","article-title":"Epidemiology of invasive streptococcus pneumoniae infections in the United States, 1995\u20131998: opportunities for prevention in the conjugate vaccine era","volume":"285","author":"Robinson","year":"2001","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0245","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 1997 [web-based report], 03-May-1999. http:\/\/www.cdc.gov\/ncidod\/dbmd\/abcs."},{"key":"10.1016\/j.vaccine.2015.04.025_bib0250","doi-asserted-by":"crossref","first-page":"6557","DOI":"10.1016\/j.vaccine.2007.06.044","article-title":"WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries. 26\u201327 October 2006, Geneva","volume":"25","author":"Cherian","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0255","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O\u2019Brien","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0260","doi-asserted-by":"crossref","first-page":"4955","DOI":"10.1016\/j.vaccine.2010.05.030","article-title":"Clinical and economic burden of pneumococcal disease in older US adults","volume":"28","author":"Weycker","year":"2010","journal-title":"Vaccine"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2015.04.025_bib0265","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2165\/00002512-199915001-00003","article-title":"Pneumococcal vaccination for older adults. The first 20 years","volume":"15","author":"Fedson","year":"1999","journal-title":"Drugs Aging"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0270","first-page":"64","article-title":"Recommendations of the immunization practices advisory committee pneumococcal polysaccharide vaccine","volume":"38","author":"Center for Disease Control","year":"1989","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0275","series-title":"Vaccines","first-page":"504","article-title":"Pneumococcal conjugate vaccine and pneumococcal common protein vaccines","author":"Klugman","year":"2012"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0280","series-title":"Vaccines","first-page":"542","article-title":"Pneumococcal polysaccharide vaccines","author":"Jackson","year":"2012"},{"issue":"RR-4","key":"10.1016\/j.vaccine.2015.04.025_bib0285","first-page":"1","article-title":"Recommendations of the Advisory Committee on Immunization Practices (ACIP): Use of vaccines and immune globulins in persons with altered immunocompetence","volume":"42","author":"Centers for Disease Control and Prevention","year":"1993","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"(RR-8):i-iv","key":"10.1016\/j.vaccine.2015.04.025_bib0290","first-page":"1","article-title":"Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"46","author":"Centers for Disease Control and Prevention","year":"1997","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0295","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1086\/431521","article-title":"The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults","volume":"192","author":"Kyaw","year":"2005","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0300","first-page":"217","article-title":"Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines","volume":"16","author":"Lynch","year":"2010","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0305","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/003335491112600217","article-title":"Mortality reductions for older adults differ by race\/ethnicity and gender since the introduction of adult and pediatric pneumococcal vaccines","volume":"126","author":"Soneji","year":"2011","journal-title":"Public Health Rep"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0310","first-page":"78","article-title":"Pneumococcal vaccination in adults: rationale, state of the art and perspectives","volume":"53","year":"2012","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0315","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa022823","article-title":"Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine","volume":"348","author":"Whitney","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0320","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1086\/521626","article-title":"Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998\u20132004","volume":"196","author":"Hicks","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0325","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0330","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/INF.0b013e31824de9f6","article-title":"The worldwide impact of the seven-valent pneumococcal conjugate vaccine","volume":"31","author":"Fitzwater","year":"2012","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0335","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0340","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1128\/CVI.00415-08","article-title":"Optimization and validation of a multiplex, electrochemiluminescence-based detection assay for the quantitation of immunoglobulin G serotype-specific antipneumococcal antibodies in human serum","volume":"16","author":"Marchese","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0345","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1128\/CVI.00112-06","article-title":"Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies","volume":"13","author":"Burton","year":"2006","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0350","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.inf.0000129685.04847.94","article-title":"Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente","volume":"23","author":"Black","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0355","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1001\/jama.294.16.2043","article-title":"Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine","volume":"29","author":"Lexau","year":"2005","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0360","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.vaccine.2005.07.095","article-title":"Impact of pediatric vaccination with pneumococcal conjugate vaccine on the risk of bacteremic pneumococcal pneumonia in adults","volume":"24","author":"Metlay","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0365","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.3201\/eid1907.121830","article-title":"Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999\u20132011","volume":"19","author":"Richter","year":"2013","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0370","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1542\/peds.2014-0473","article-title":"Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine","volume":"134","author":"Iroh Tam","year":"2014","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0375","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1128\/AAC.03344-14","article-title":"Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States","volume":"58","author":"Richter","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0380","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/infdis\/jiu213","article-title":"Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire Region of England","volume":"210","author":"Moore","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0385","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.vaccine.2014.11.011","article-title":"Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001\u20132012","volume":"33","author":"Lepoutre","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0390","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/cid\/ciu524","article-title":"Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality","volume":"59","author":"Harboe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0395","doi-asserted-by":"crossref","first-page":"e112211","DOI":"10.1371\/journal.pone.0112211","article-title":"All-cause pneumonia hospitalizations in children <2 years old in Sweden, 1998 to 2012: impact of pneumococcal conjugate vaccine introduction","volume":"9","author":"Berglund","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0400","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1016\/j.vaccine.2012.06.068","article-title":"Four years of universal pneumococcal conjugate vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children","volume":"30","author":"van der Linden","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0405","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1139\/cjm-2013-0614","article-title":"Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010\u20132012","volume":"59","author":"Demczuk","year":"2013","journal-title":"Can J Microbiol"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0410","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.vaccine.2013.12.003","article-title":"Serotype distribution and antimicrobial susceptibilities of nasopharyngeal isolates of Streptococcus pneumoniae from healthy children in the 13-valent pneumococcal conjugate vaccine era","volume":"32","author":"Zuccotti","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0415","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.vaccine.2014.03.054","article-title":"Reduced incidence of invasive pneumococcal disease after introduction of the 13-valent conjugate vaccine in Navarre, Spain, 2001\u20132013","volume":"32","author":"Guevara","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0420","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1016\/j.vaccine.2014.03.065","article-title":"Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance","volume":"32","author":"Ben-Shimol","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0425","doi-asserted-by":"crossref","first-page":"e111129","DOI":"10.1371\/journal.pone.0111129","article-title":"Serotypes and genotypes of invasive streptococcus pneumonia before and after PCV10 implementation in Southern Brazil","volume":"9","author":"Caier\u00e3o","year":"2014","journal-title":"PLOS ONE"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0430","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(07)60564-9","article-title":"Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis","volume":"369","author":"Grijalva","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0435","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0140-6736(07)61119-2","article-title":"Herd immunity after pneumococcal conjugate vaccine","volume":"370","author":"Albrich","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0440","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00309-10","article-title":"Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States","volume":"2","author":"Simonsen","year":"2011","journal-title":"mBio"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0445","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1056\/NEJMoa1209165","article-title":"U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination","volume":"369","author":"Griffin","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0450","first-page":"78","article-title":"Pneumococcal vaccination in adults: rationale, state of the art and perspectives","volume":"53","author":"Icardi","year":"2012","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0455","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.4161\/hv.28633","article-title":"Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine when administered to healthy Japanese adults aged \u226550 years","volume":"10","author":"Shiramoto","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0460","doi-asserted-by":"crossref","first-page":"6164","DOI":"10.1016\/j.vaccine.2007.06.004","article-title":"Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults","volume":"25","author":"Scott","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0465","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-na\u00efve adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.04.025_bib0470","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1097\/INF.0000000000000516","article-title":"Safety, Tolerability, and Immunogenicity of 15-Valent Pneumococcal Conjugate Vaccine in Toddlers Previously Vaccinated with 7-Valent Pneumococcal Conjugate Vaccine","volume":"34","author":"Sobanjo-ter Meulen","year":"2015","journal-title":"Pediatr Infect Dis J"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004788?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15004788?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,23]],"date-time":"2018-09-23T06:26:57Z","timestamp":1537684017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15004788"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":47,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0264410X15004788"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.025","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, tolerability, and immunogenicity of 15-valent pneumococcal conjugate vaccine in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}